Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Inventory (2020 - 2025)

RxSight (RXST) has disclosed Change in Inventory for 6 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 690.44% year-over-year to $3.2 million, compared with a TTM value of $11.5 million through Dec 2025, up 129.96%, and an annual FY2025 reading of $11.5 million, up 129.96% over the prior year.
  • Change in Inventory was $3.2 million for Q4 2025 at RxSight, down from $4.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $4.0 million in Q3 2022 and bottomed at -$1.4 million in Q4 2021.
  • Average Change in Inventory over 5 years is $1.4 million, with a median of $1.4 million recorded in 2021.
  • The sharpest move saw Change in Inventory skyrocketed 5282.14% in 2021, then tumbled 566.01% in 2023.
  • Year by year, Change in Inventory stood at -$1.4 million in 2021, then soared by 85.5% to -$203000.0 in 2022, then crashed by 566.01% to -$1.4 million in 2023, then soared by 130.18% to $408000.0 in 2024, then soared by 690.44% to $3.2 million in 2025.
  • Business Quant data shows Change in Inventory for RXST at $3.2 million in Q4 2025, $4.0 million in Q3 2025, and $2.7 million in Q2 2025.